INTRODUCTION AND OBJECTIVES: Whether or not adding systematic biopsies to targeted cores in patients with a lesion detected at mpMRI of the prostate is still debated. We aimed to identify patients who can avoid systematic biopsy (SBx) at the time of mpMRI targeted biopsy (TBx) relying on individual patient probability to harbour clinically significant prostate cancer (csPCa) outside the index lesion (IL).
METHODS: We identified 359 patients who underwent mpMRI of the prostate with subsequent fusion TBx and concomitant SBx at a single European Centre between 2013 and 2018. All patients either were biopsy naive or had previous negative biopsy and all had a negative digital rectal examination. The study outcome was csPCa, defined as Gleason at biopsy!3þ4 outside the IL. Multivariable logistic regression analysis (MVA) was performed to develop a predictive model for the study outcome. Predictors included age at biopsy, PSA, prostate volume, PIRADS score, number of MRI lesions and previous biopsy history. Multivariable-derived coefficients were used to develop a novel risk-calculator. External validation of the model was performed into a North American population of 462 patients, using the predetermined regression coefficient. The model was evaluated using the AUC, calibration plot, and decision-curve analyses (DCA) both in development and validation cohort.
RESULTS: Overall, csPCa detection rate was 53.5%. The csPCa detection rate for SBx was 39.8%. At MVA, age at biopsy (OR: 1.03), PSA (OR: 1.05), prostate volume (OR: 0.98), previous negative biopsy (OR: 0.4), PIRADS 4 (OR: 3.8) and 5 (OR: 9.3), were independent predictors of csPCa outside the IL. The multivariable model had an AUC of 0.78 and the calibration plot was good. Omitting SBx in patients with a calculated risk <15%, would have spared 16% of TRUSBx at the cost of missing 7% of csPCa. External validation of our nomogram showed an AUC of 0.74. The application of our riskcalculator in the validation cohort would have spared 21% of SBx at the cost of missing 5% of csPCa. Nonetheless, when evaluating the clinical utility of the model using DCA, no net benefit was observed for threshold probability investigated (<15%) compared to the standard of care (performing SBx in addition to TBx in all patients), both in development and validation cohort.
CONCLUSIONS: Despite good accuracy, our model failed to demonstrate any clinical net benefit. Given the lack of clinical utility of our tool, the combination of TBx and SBx should always considered as the best available approach to reduce the risk of misdiagnosis of csPCa. within the IL across different PI-RADS score. We hypothesized that one target core might be enough for csPCa detection.
METHODS: We relied on 404 patients who underwent MRI of the prostate with subsequent target and concomitant systematic biopsy at two tertiary referral Centres between 2013 and 2018. Included men were either biopsy naive or received a previous negative biopsy. Moreover, all had a negative DRE and a single MRI detected IL which was targeted with up to 4 cores. All MRI were scored according to PI-RADS system. The study outcome was csPCa within the IL, defined as Gleason at biopsy !3þ4 at targeted biopsy. Multivariable logistic regression analyses (MVA) were performed to develop three predictive models within each PI-RADS score (namely, 3,4 and 5) separately. Predictors included age at biopsy, PSA density, volume of the IL and number of target cores. Non-parametric curve fitting methods were used to explore the relationship between the number of target cores and the probability to detect csPCa within the IL.
RESULTS: Overall, 154 (38%), 185 (46%) and 65 (16%) of all lesions were PI-RADS 3, 4 and 5, respectively. The csPCa detection rate within the IL was 18 (n[28), 52 (n[97) and 74 % (n[48) in PI-RADS 3, 4 and 5, respectively. The median number of target cores was 3 (Range: 1-4) in all three PI-RADS groups. The number of target cores was not an independent predictor of csPCa within the IL in all three predictive models (all p!0.4). Figure 1 depicts the probability of csPCa within the IL plotted against the number of target cores after accounting for confounders and stratified according to PI-RADS score. Increasing the number of target cores was not associated with a significant increase of the probability to detect csPCa within IL in all groups (all p!0.4).
CONCLUSIONS: The number of target cores is not associated with the probability to detect csPCa across all PI-RADS score of the IL. Therefore, according to our results, one single core might be enough to obtain an accurate targeted sampling regardless of the features of the IL.
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MP36-15 TO BIOPSY, OR NOT TO BIOPSY, THAT IS THE QUESTION: RISK STRATIFICATION OF PATIENTS WITH A NEGATIVE MRI
INTRODUCTION AND OBJECTIVES: The use of multiparametric MRI (mp-MRI) of the prostate has been shown to aid in the detection of clinically significant prostate cancer (CSPC). A subset of patients without a suspicious lesion on mp-MRI will harbor occult CSPC. Our objectives were twofold: to determine predictive utility of prostate mp-MRI and to determine the value of PSA Density (PSAD) in improving risk stratification for CSPC in patients with a negative MRI that undergo a prostate biopsy.
METHODS: We performed a retrospective review of a database of 4294 patients who underwent a prostate mp-MRI from 2012 -2016. Patients with a previous prostate cancer diagnosis were excluded. Sensitivity (Sn), specificity (SP), PPV, and NPV were calculated for mp-MRI of the prostate, with PI RADS 1 or 2 being considered negative and 3-5 considered positive. Analysis was then performed on patients with negative MRI that had a subsequent prostate biopsy.
